A comparative study of the efficacy and safety of romosozumab and teriparatide for glucocorticoid-induced osteoporosis 1

A comparative study of the efficacy and safety of romosozumab and teriparatide for glucocorticoid-induced osteoporosis 1 - A comparative study of the efficacy and safety of romosozumab and teriparatide for glucocorticoid-induced osteoporosis 1

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000056386

Enrollment

100

Registered

2025-02-01

Start date

2025-08-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glucocorticoid-induced osteoporosis

Interventions

Romosozumab group: Patients receive romosozumab subcutaneously. After 52 weeks of treatment, romosozumab will be discontinued and denosumab will be started. At week 156, final observation is performed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients 40 years of age or older newly initiating glucocorticoids, meeting the criteria for initiation of pharmacological therapy for glucocorticoid-induced osteoporosis 2) Patients who have provided written informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with contraindications to romosozumab or denosumab. 2) Patients with active infection or malignancy. 3) Patients who are currently pregnant, lactating, or willing to get pregnant. 4) Patients who do not give consent to this study. 5) Patients previously treated with romosozumab or teriparatide

Design outcomes

Primary

Measure	Time frame
The percent change of bone mineral density of the lumbar spine (L2-4), femoral neck and total hip at 52 and 104 weeks in the romosozumab and teriparatide groups.	—

Countries

Japan

Contacts

Public ContactMai Kawazoe

Toho University School of Medicine Division of Rheumatology, Department of Internal Medicine

mai.kawazoe@med.toho-u.ac.jp03-3462-4151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026